BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 35163633)

  • 1. Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints.
    Mathew EN; Berry BC; Yang HW; Carroll RS; Johnson MD
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
    Karim R; Palazzo C; Evrard B; Piel G
    J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.
    Oberoi RK; Parrish KE; Sio TT; Mittapalli RK; Elmquist WF; Sarkaria JN
    Neuro Oncol; 2016 Jan; 18(1):27-36. PubMed ID: 26359209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of convection enhanced delivery of toxins in humans.
    Mehta AI; Choi BD; Raghavan R; Brady M; Friedman AH; Bigner DD; Pastan I; Sampson JH
    Toxins (Basel); 2011 Mar; 3(3):201-6. PubMed ID: 22069706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel delivery strategies for glioblastoma.
    Zhou J; Atsina KB; Himes BT; Strohbehn GW; Saltzman WM
    Cancer J; 2012; 18(1):89-99. PubMed ID: 22290262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
    Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convection-enhanced delivery for glioblastoma: targeted delivery of antitumor therapeutics.
    Ung TH; Malone H; Canoll P; Bruce JN
    CNS Oncol; 2015; 4(4):225-34. PubMed ID: 26103989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convection-enhanced drug delivery for glioblastoma: a review.
    D'Amico RS; Aghi MK; Vogelbaum MA; Bruce JN
    J Neurooncol; 2021 Feb; 151(3):415-427. PubMed ID: 33611708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioscaffold-based study of glioblastoma cell behavior and drug delivery for tumor therapy.
    Tran K; Brice R; Yao L
    Neurochem Int; 2021 Jul; 147():105049. PubMed ID: 33945833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme.
    White E; Bienemann A; Taylor H; Hopkins K; Cameron A; Gill S
    Contemp Clin Trials; 2012 Mar; 33(2):320-31. PubMed ID: 22101221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.
    Drapeau A; Fortin D
    Curr Cancer Drug Targets; 2015; 15(9):752-68. PubMed ID: 26077730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vesicular systems employing natural substances as promising drug candidates for MMP inhibition in glioblastoma: A nanotechnological approach.
    Agarwal S; Muniyandi P; Maekawa T; Kumar DS
    Int J Pharm; 2018 Nov; 551(1-2):339-361. PubMed ID: 30236647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of nanoparticles for drug delivery in glioblastoma multiforme.
    Jain KK
    Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
    Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies.
    Jahangiri A; Chin AT; Flanigan PM; Chen R; Bankiewicz K; Aghi MK
    J Neurosurg; 2017 Jan; 126(1):191-200. PubMed ID: 27035164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel drug delivery strategies in neuro-oncology.
    Bidros DS; Vogelbaum MA
    Neurotherapeutics; 2009 Jul; 6(3):539-46. PubMed ID: 19560743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted drug delivery for treatment and imaging of glioblastoma multiforme.
    Stukel JM; Caplan MR
    Expert Opin Drug Deliv; 2009 Jul; 6(7):705-18. PubMed ID: 19538036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
    Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
    Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.